References
1. Safi F, Roscher R, Beger HG. The clinical relevance of the tumor marker CA 19-9 in the diagnosing and monitoring of pancreatic carcinoma. Bull Cancer 1990;77:83–91.Search in Google Scholar
2. Jalanko H, Kuusela P, Roberts P, Sipponen P, Haglund CA, Mäkelä O. Comparison of a new tumour marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases. J Clin Pathol 1984;37: 218–22.10.1136/jcp.37.2.218Search in Google Scholar PubMed PubMed Central
3. Bertino G, Ardiri AM, Calvagno GS, Malaguarnera G, Interlandi D, Vacante M, et al. Carbohydrate 19.9 antigen serum levels in liver disease. Biomed Res Int 2013;2013:531640.10.1155/2013/531640Search in Google Scholar PubMed PubMed Central
4. Sheen-Chen SM, Sun CK, Liu YW, Eng HL, Ko SF, Kuo CH. Extremely elevated CA19-9 in acute cholangitis. Dig Dis Sci 2007;52:3140–2.10.1007/s10620-006-9164-7Search in Google Scholar PubMed
5. ARCHITECT SYSTEM. Package insert instructions of CA 19-9XR. Abbott 2K91, p 6.Search in Google Scholar
6. Al-Dhabi NA. Heavy metal analysis in commercial Spirulina products for human consumption. Saudi J Biol Sci 2013;20: 383–8.10.1016/j.sjbs.2013.04.006Search in Google Scholar PubMed PubMed Central
7. Passerini R, Cassatella MC, Boveri S, Salvatici M, Radice D, Zorzino L, et al. The pitfalls of CA19-9: routine testing and comparison of two automated immunoassays in a reference oncology center. Am J Clin Pathol 2012;138:281–7.10.1309/AJCPOPNPLLCYR07HSearch in Google Scholar PubMed
©2015 by De Gruyter
